Atalanta Therapeutics
Boston, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $97M
Overview
Developing RNAi therapeutics with targeted delivery for genetically defined neurodegenerative diseases.
NeuroscienceRare Disease
Technology Platform
Proprietary RNAi delivery platforms, including conjugated siRNAs, engineered to cross the blood-brain barrier and target specific neuronal cell types.
Funding History
1Total raised:$97M
Series A$97M
Opportunities
Large unmet medical need in neurodegenerative diseases and potential for platform application across multiple CNS disorders.
Risk Factors
High technical risk associated with delivering drugs to the brain and demonstrating clinical efficacy in progressive neurological conditions.
Competitive Landscape
Faces competition from other RNAi/biologics companies targeting CNS (e.g., Alnylam, Ionis) and gene therapy approaches, but its specialized delivery tech is a key differentiator.